Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COLUMN
COLUMN
- How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
- Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
- Emerging Immunotherapy of Cancer: 2
April 11, 2014
- Emerging Immunotherapy of Cancer: 1
April 10, 2014
- Sun Tzu and the Art of Interviewing
March 18, 2014
- 2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
- The Time Is Now for Medical Affairs
January 17, 2014
- Blue Ocean Recruiting
December 20, 2013
- Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
- A World of Opportunity for the Brave
November 1, 2013
- Does HR Have an Image Problem?
September 20, 2013
- Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
- Watch out for the Gorilla when Hiring Talent
July 19, 2013
- Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
- Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
- An Insider’s Perspective on Hiring in Japan
April 26, 2013
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…